RxDoctor Payments Data

Amanda Ford, APRN

Family · Hot Springs, ARNPI 1417532292

Payments from drug & device makers

$7,473in general payments, 2019–2025

Across 520 payments — averaging $14.37 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$1K
  • AstraZeneca$1K
  • Lilly USA, LLC$544
  • Otsuka America Pharmaceutical, Inc.$524
  • Pfizer$451
  • Dexcom, Inc.$423
  • plus $3K from 35 others

What the payments were for

  • Food & beverage$7,473100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$7,473 in reported general payments places this provider in the 95th percentile of 2,103 family providers in Arkansas.

See all family providers in Arkansas

Medicare billing

Part B allowed, 2024
$70,203
Medicare patients
416
Services billed
2,709

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
RexultiBrexpiprazole24$36,906
OzempicSemaglutide27$33,406
FarxigaDapagliflozin Propanediol19$22,848
MounjaroTirzepatide17$22,308
JanuviaSitagliptin Phosphate25$21,702
Trelegy ElliptaFluticasone/Umeclidin/Vilanter29$19,118
EliquisApixaban14$12,075
JardianceEmpagliflozin15$10,029
GemtesaVibegron12$7,725
SymbicortBudesonide/Formoterol Fumarate11$2,763
Albuterol Sulfate HfaAlbuterol Sulfate113$2,644
Ventolin HfaAlbuterol Sulfate35$2,036
Omeprazole140$1,948
Atorvastatin Calcium240$1,912
Potassium Chloride97$1,597

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Otsuka America Pharmaceutical, Inc.Rexulti$524$36,90624 claims
Novo NordiskOzempic$357$33,40627 claims
AstraZenecaFarxiga, Symbicort$1,084$25,61230 claims
Lilly USA, LLCMounjaro$544$22,30817 claims
MerckJanuvia$35$21,70225 claims
GSKTrelegy Ellipta$126$19,11829 claims
PfizerEliquis, Paxlovid$451$13,43531 claims
Boehringer IngelheimJardiance$28$10,02915 claims
Sumitomo Pharma America, Inc.Gemtesa$290$7,72512 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 2,103 family providers in Arkansas.

Other family in Hot Springs

See the full list for Arkansas

Where these figures come from

Is this you, or does something look wrong? →